Skip to main content
Clinical Trials/NCT05328895
NCT05328895
Completed
N/A

Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease: Randomized Trial Controlled

Beijing Tongren Hospital1 site in 1 country92 target enrollmentOctober 1, 2020
ConditionsMeniere Disease

Overview

Phase
N/A
Intervention
Not specified
Conditions
Meniere Disease
Sponsor
Beijing Tongren Hospital
Enrollment
92
Locations
1
Primary Endpoint
Pure tone thresholds.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the patients Meniere disease. Methods: We enrolled 88 patients at Beijing TongRen Hospital. All treatments were self-administered by the patients at home after training at the hospital. Patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry, visual scale of ear stuffiness and SF-36 were performed to evaluate the therapeutic effects. A difference of P < 0.05 was considered statistically significant.

Registry
clinicaltrials.gov
Start Date
October 1, 2020
End Date
May 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Beijing Tongren Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>=18 and Age \<=
  • Clinical diagnosis of meniere disease.

Exclusion Criteria

  • History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
  • History of Otorhinolaryngology surgery.
  • Pregnant or lactating women.

Outcomes

Primary Outcomes

Pure tone thresholds.

Time Frame: Change from Baseline level of Pure tone thresholds at 12-weeks post-therapy.

The pure tone thresholds was performed in a sound-attenuated, double-walled booth with circumaural headphones (Sennheiser HD 280 for frequencies from 250 to 8000 Hz and Sennheiser HD 200 for frequencies from 8000 to 14000 Hz; Sennheiser, Old Lyme, USA) on a certified and calibrated audiometric system (Interacoustics, Middelfart, Denmark). Thresholds were measured using a probe-detection paradigm with pure tones presented for 250 ms at frequencies of 250, 500, 1000, 2000, 4000, 8000 Hz for each ear. To determine the LDL, the volume was set to 75 dB at 1000 Hz and then continuously raised in 5 dB steps (every 5 s) until the subject gave the signal that this volume was uncomfortable. When the volume exceeded 110 dB the test was stopped to prevent any hearing damage. The severity of hearing impairment was calculated as mild (20-40 dB), moderate (41-70 dB), severe (71-95 dB) and profound (\>95 dB). Normal hearing was defined as pure-tone thresholds less than 20 dB.

Tinnitus Handicap Inventory (THI)

Time Frame: Change from Baseline scores of THI at 12-weeks post-therapy.

The THI is a 25-items, self-reported questionnaire regarding tinnitus handicap in daily life. The questionnaire comprises a 12-item functional subscale, an 8-item emotional subscale, and a 5-item catastrophic subscale. The three answer options are "yes," "sometimes," and "no," with scores of 4, 2, and 0, respectively. The overall score is the sum of 25 items (Range: 0-100). Higher scores equate to greater severity of tinnitus symptoms. measure the subjective tinnitus symptoms.

Dizziness Handicap Inventory (DHI)

Time Frame: Change from Baseline scores of DHI at 12-weeks post-therapy.

The DHI is 25-items self-reported questionnaire that used to evaluate the functional, emotional, and physical impact of dizziness on patients' daily life. Among the overall 25 items of questions, 9 items are emotional related, 9 items are functional related, and 7 items are physical related questions. The three answer options are "yes," "sometimes," and "no," with scores of 4, 2, and 0, respectively. The overall score is the sum of 25 items (Range: 0-100). Higher scores equate to greater severity of dizziness symptoms.

Visual analogue scale (VAS)

Time Frame: Change from Baseline scores of VAS of aural fullness at 12-weeks post-therapy.

The VAS scale of aural fullness consists of a 100 mm straight line with defined endpoints ("no aural fullness" and "worst aural fullness imaginable") on which the patients were asked to mark their experienced aural fullness (results in mm) at the actual time ("VAS now"). The higher VAS score (Range: 0-100) is correlated with a severe aural fullness.

Secondary Outcomes

  • Video head impulse test (vHIT)(Change from Baseline number of pathological saccades and values of vHIT at 12-weeks post-therapy.)
  • The caloric test(Change from Baseline number of abnormal Unilateral Weakness (UW) at 12-weeks post-therapy.)
  • The Short Form Health Survey (SF36)(Change from Baseline scores of SF-36 at 12-weeks post-therapy.)

Study Sites (1)

Loading locations...

Similar Trials